Arrowhead Pharmaceuticals Inc. (ARWR)

27.51
0.38 1.36
NASDAQ : Health Technology
Prev Close 27.89
Open 27.98
Day Low/High 27.29 / 28.19
52 Wk Low/High 10.41 / 27.97
Volume 1.92M
Avg Volume 1.97M
Exchange NASDAQ
Shares Outstanding 94.81M
Market Cap 2.51B
EPS -0.70
P/E Ratio 368.86
Div & Yield N.A. (N.A)
3 Stocks Under $10 Triggering Breakout Trades

3 Stocks Under $10 Triggering Breakout Trades

Keep these under-$10 stocks on your breakout trading radar.

Trade-Ideas: Arrowhead Research (ARWR) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Arrowhead Research (ARWR) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a weak on high relative volume candidate

First Week of ARWR September 18th Options Trading

First Week of ARWR September 18th Options Trading

Investors in Arrowhead Research Corp saw new options begin trading this week, for the September 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 193 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

Arrowhead Research (ARWR): Heavy Pre-Market Activity

Arrowhead Research (ARWR): Heavy Pre-Market Activity

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a pre-market mover with heavy volume candidate

Arrowhead Acquires Novartis' RNAi Research And Development Portfolio

Arrowhead Acquires Novartis' RNAi Research And Development Portfolio

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced the acquisition of Novartis' entire RNAi research and development portfolio and associated...

Arrowhead To Present At 2015 Barclays Global Healthcare Conference

Arrowhead To Present At 2015 Barclays Global Healthcare Conference

Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Arrowhead's president and chief executive officer Christopher Anzalone, Ph.

'Mad Money' Lightning Round: Stick With Restoration Hardware

'Mad Money' Lightning Round: Stick With Restoration Hardware

Cramer says 3M is a buy, buy, buy but Encana and GoPro are not for him.

Arrowhead Begins Phase 1 Trial Of ARC-AAT For Treatment Of Liver Disease Associated With Alpha-1 Antitrypsin Deficiency

Arrowhead Begins Phase 1 Trial Of ARC-AAT For Treatment Of Liver Disease Associated With Alpha-1 Antitrypsin Deficiency

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it has initiated dosing in a Phase 1 clinical trial of ARC-AAT, the company's candidate...

Arrowhead To Present At 2015 RBC Capital Markets' Global Healthcare Conference

Arrowhead To Present At 2015 RBC Capital Markets' Global Healthcare Conference

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Arrowhead's chief operating officer Bruce Given, M.

4 Biotech Stocks Under $10 to Trade for Breakouts: Sophiris, Atossa and More

4 Biotech Stocks Under $10 to Trade for Breakouts: Sophiris, Atossa and More

Keep these under-$10 biotech stocks on your breakout trading radar.

Arrowhead Reports Fiscal 2015 First Quarter Financial Results

Arrowhead Reports Fiscal 2015 First Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2015 first quarter ended December 31, 2014.

Arrowhead To Report Fiscal 2015 First Quarter Financial Results

Arrowhead To Report Fiscal 2015 First Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2015 first quarter ended December...

Insider Trading Alert - CFX, ARWR And FMI Traded By Insiders

Insider Trading Alert - CFX, ARWR And FMI Traded By Insiders

Stocks with insider trader activity include CFX, ARWR and FMI

Arrowhead Research (ARWR) Stock Plummets Today After FDA Partial Clinical Hold

Arrowhead Research (ARWR) Stock Plummets Today After FDA Partial Clinical Hold

Shares of Arrowhead Research (ARWR) plunged in morning trading Monday after the FDA instituted a partial clinical hold on the drug developer's potential hepatitis B treatment.

Arrowhead Provides Update On IND For ARC-520 Phase 2b Study

Arrowhead Provides Update On IND For ARC-520 Phase 2b Study

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the U.

Arrowhead Research (ARWR) Highlighted As Today's Perilous Reversal Stock

Arrowhead Research (ARWR) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

Today's Weak On High Volume Stock: Arrowhead Research (ARWR)

Today's Weak On High Volume Stock: Arrowhead Research (ARWR)

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a weak on high relative volume candidate

Arrowhead Research (ARWR) Is Strong On High Volume Today

Arrowhead Research (ARWR) Is Strong On High Volume Today

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a strong on high relative volume candidate

2015 Biotech Drug/Stock Outlook: Here's What You Need to Know

2015 Biotech Drug/Stock Outlook: Here's What You Need to Know

To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.

Arrowhead Files IND For RNAi Therapeutic ARC-520 To Begin Phase 2b Multiple-Dose Studies In Chronic Hepatitis B Patients

Arrowhead Files IND For RNAi Therapeutic ARC-520 To Begin Phase 2b Multiple-Dose Studies In Chronic Hepatitis B Patients

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it submitted an Investigational New Drug (IND) application to the U.

Arrowhead Research (ARWR) Showing Signs Of Perilous Reversal Today

Arrowhead Research (ARWR) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

CORRECTING and REPLACING Arrowhead Appoints Patrick O'Brien as General Counsel

CORRECTING and REPLACING Arrowhead Appoints Patrick O'Brien as General Counsel

Arrowhead Research Corporation corrects its press release issued on December 4, 2014, to correct the statement regarding "inducement" grants.

INVESTOR ALERT: Class Action Lawsuit Against Arrowhead Research Corporation Announced By Law Offices Of Howard G. Smith

INVESTOR ALERT: Class Action Lawsuit Against Arrowhead Research Corporation Announced By Law Offices Of Howard G. Smith

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of purchasers of the common stock of Arrowhead ...

INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors Of The Lead Plaintiff Deadline In The Class Action Lawsuit Against Arrowhead Research Corporation

INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors Of The Lead Plaintiff Deadline In The Class Action Lawsuit Against Arrowhead Research Corporation

Glancy Binkow & Goldberg LLP reminds investors of Arrowhead Research Corporation ("Arrowhead" or the "Company") (NASDAQ:ARWR) that purchasers of Arrowhead common stock between August 12, 2014 and October...

Arrowhead Reports Fiscal 2014 Year End Financial Results

Arrowhead Reports Fiscal 2014 Year End Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2014 fourth quarter and year ended September 30, 2014.

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against Arrowhead Research Corp. And Its Board Of Directors And A Lead Plaintiff Deadline Of December 9, 2014

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against Arrowhead Research Corp. And Its Board Of Directors And A Lead Plaintiff Deadline Of December 9, 2014

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Arrowhead Research Corp.

SHAREHOLDER ALERT: Investigation On Behalf Of Arrowhead Research Corporation Investors Announced By Law Offices Of Howard G. Smith

SHAREHOLDER ALERT: Investigation On Behalf Of Arrowhead Research Corporation Investors Announced By Law Offices Of Howard G. Smith

Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Arrowhead Research Corporation ("Arrowhead" or the "Company") (NASDAQ:ARWR).

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Research Corp. To Contact Brower Piven Before The December 9, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Research Corp. To Contact Brower Piven Before The December 9, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on...

TheStreet Quant Rating: C+ (Hold)